CONFIRM Progesterone Receptor (PR)

CONFIRM anti-PR (1E2) Primary Antibody is intended for laboratory use for the qualitative detection of progesterone receptor(PR) antigen in sections of formalin-fixed, paraffin-embedded tissue on a Ventana automated slide stainer with Ventana detection kits and ancillary reagents. CONFIRM anti-PR (1E2) that recognizes the A and B forms of human progesterone receptor and is indicated as an aid in the management, prognosis, and prediction of therapy outcome of breast cancer. One of the important markers in breast cancer today is progesterone receptor (PR), due to its role in determining the functionality of estrogen receptors present in breast cancer cells. The presence of estrogen receptor (ER), however, does not guarantee a response to endocrine therapy. Half of all patients with ER positive primary tumors fail to respond. In tumor cells, genetic expression is often inaccurate, leading to variant protein expression. It is proposed that mutant ER, that no longer bind estrogen or that no longer perform signal transduction, may be the cause of the failure to respond to endocrine therapy. One way to evaluate the functionality of the ER present in a breast carcinoma is to determine if proteins regulated by ER are expressed. Progesterone receptor is such a protein, and has been used to monitor for functional ER for many years.

References

1. Bevitt DJ, Milton ID, et al., J. Pathol. 83(2):228-232, 1997.
2. Dickson RB, Lippman ME, et al., Kluwer Acad, Publ. 1992; 285-286.
3. Wei LL, et al., Cancer Res. 54(2):340-3, 1994.
4. Doglioni C, et al., Am. J. Pathol. 137(5):999-1005, 1990.
5. Greene GL, et al., Immun. Appr. Diag. and Ther. Breast Cancer. 119-135, 1987.
6. Press MF, Greene GL, et al., Endocrinology. 122(3):1165-1175, 1988.
7. Winborn WB, Sheridan PJ, et al., Pancreas. 2(3):289-94, 1987.
8. Money SR, Muss W, et al., Surgery. 106(6):975-8, 1989.
9. Roche PC, et al., Mayo Clin. Proc. 69(1):57-58, 1994.
10. PDQ. http://icisun.nci.nih?t_cancer_Physician.html.
11. Horwitz KB, et al., J. Steroid Biochem. Mol. Biol. 49(4-6):295-302, 1994.
12. Van Agthoven T, Timmermans M, et al., Int. J. Cancer. 63(6):790-793, 1995.